SEARCH:   Advanced

Blood, 15 December 2008, Vol. 112, No. 13, pp. 4824-4831. Prepublished online as a Blood First Edition Paper on September 17, 2008; DOI 10.1182/blood-2008-04-153189. This Article Full Text Full Text (PDF) Supplemental Appendix All Versions of this Article: blood-2008-04-153189v1 112/13/4824    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Salles, G. Articles by Foussard, C. Search for Related Content PubMed PubMed Citation Articles by Salles, G. Articles by Foussard, C. Related Collections Neoplasia Free Research Articles Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL TRIALS AND OBSERVATIONS Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study Gilles Salles1, Nicolas Mounier2, Sophie de Guibert3, Franck Morschhauser4, Chantal Doyen5, Jean-François Rossi6, Corinne Haioun7, Pauline Brice8, Béatrice Mahé9, Reda Bouabdallah10, Bruno Audhuy11, Christophe Ferme12, Caroline Dartigeas13, Pierre Feugier14, Catherine Sebban15, Luc Xerri10, and Charles Foussard16 1 Hospices Civils de Lyon and Université Lyon 1, Lyon, France; 2 Centre Hospitalier Universitaire de Nice, Nice, France; 3 Centre Hospitalier Universitaire de Rennes, Rennes, France; 4 Centre Hospitalier Universitaire de Lille, Lille, France; 5 Cliniques Universitaires (UCL) de Mont-Godinne, Yvoir, Belgium; 6 Centre Hospitalier Universitaire de Montpellier, Montpellier, France; 7 Hôpital Henri-Mondor, Assistance Publique-Hopitaux de Paris and Université Paris XII, Paris, France; 8 Hôpital Saint-Louis, Assistance Publique-Hopitaux de Paris, Paris, France; 9 Centre Hospitalier Universitaire de Nantes, Nantes, France; 10 Institut Paoli Calmettes, Marseille, Marseille, France; 11 Centre Hospitalier (CH) de Colmar, Colmar, France; 12 Institut Gustave Roussy, Villejuif, France; 13 Centre Hospitalier Universitaire de Tours, Tours, France; 14 Centre Hospitalier Universitaire de Nancy, Nancy, France; 15 Centre Léon Bérard, Lyon, France; and 16 Centre Hospitalier Universitaire d'Angers, d'Angers, France The FL2000 study was undertaken to evaluate the combination of the anti-CD20 monoclonal antibody rituximab with chemotherapy plus interferon in the first-line treatment of follicular lymphoma patients with a high tumor burden. Patients were randomly assigned to receive either 12 courses of the chemotherapy regimen CHVP (cyclophosphamide, adriamycin, etoposide, and prednisolone) plus interferon-2a (CHVP+I arm) over 18 months or 6 courses of the same chemotherapy regimen combined with 6 infusions of 375 mg/m2 rituximab and interferon for the same time period (R-CHVP+I arm). After a median follow-up of 5 years, event-free survival estimates were, respectively, 37% (95% confidence interval [CI], 29%-44%) and 53% (95% CI, 45%-60%) in the CHVP+I and R-CHVP+I arm (P = .001). Five-year overall survival estimates were not statistically different in the CHVP+I (79%; 95% CI, 72%-84%) and R-CHVP+I (84%; 95% CI, 78%-84%) arms. In a multivariate regression analysis, event-free survival was significantly influenced by both the Follicular Lymphoma International Prognostic Index score (hazard ratio = 2.08; 95% CI, 1.6%-2.8%) and the treatment arm (hazard ratio = 0.59; 95% CI, 0.44%-0.78%). With a 5-year follow-up, the combination of rituximab with CHVP+I provides superior disease control in follicular lymphoma patients despite a shorter duration of chemotherapy. This study's clinical trial was registered at the National Institutes of Health website as no. NCT00136552 [ClinicalTrials.gov] . CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: H. Hochster, E. Weller, R. D. Gascoyne, T. M. Habermann, L. I. Gordon, T. Ryan, L. Zhang, N. Colocci, S. Frankel, and S. J. Horning Maintenance Rituximab After Cyclophosphamide, Vincristine, and Prednisone Prolongs Progression-Free Survival in Advanced Indolent Lymphoma: Results of the Randomized Phase III ECOG1496 Study J. Clin. Oncol., April 1, 2009; 27(10): 1607 - 1614. [Abstract] [Full Text] [PDF] A. Hagenbeek Maintenance or Eradication of Residual Disease in Indolent Lymphoma: Where Do We Stand? J. Clin. Oncol., April 1, 2009; 27(10): 1540 - 1542. [Full Text] [PDF]

	Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020